Caron, Philippe
Brue, Thierry
Raverot, Gérald
Tabarin, Antoine
Cailleux, Anne
Delemer, Brigitte
Renoult, Peggy Pierre
Houchard, Aude
Elaraki, Fatine
Chanson, Philippe
Funding for this research was provided by:
Ipsen
Article History
Received: 12 April 2018
Accepted: 15 September 2018
First Online: 29 September 2018
Change Date: 31 October 2018
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake in corresponding author name as Philippe Chanson in the affiliation section.
Compliance with ethical standards
:
: P.C. is a consultant and speaker for Ipsen, Novartis and Pfizer, and an advisory board member for Ipsen. T.B. has received institutional research support from Novo-Nordisk, Sandoz and Pfizer, consultancy or lectureship fees from Ipsen, Novartis, Strongbridge, and Pfizer, and has served as investigator for clinical trials funded by Novartis, Ipsen and Strongbridge. G.R. has received research grants from Ipsen and Novartis; has served as investigator (principal or coordinator) for clinical trials funded by Novartis and Ipsen, and is a member of Advisory Boards for Ipsen and Novartis. A.T. is a consultant for Ipsen, Novartis, and HRA Pharma and has received lecture fees from Novartis, HRA Pharma and Pfizer. A.C. has no financial disclosures. B.D. has received unrestricted research grants from Pfizer and Novartis, and has served as investigator for clinical trials funded by Novartis, Ipsen and Pfizer. B.D. is a member of advisory board for Ipsen, Novartis and Pfizer and has given lectures for Ipsen, Novartis and Pfizer. PPR has served as coinvestigator for clinical trials funded by Pfizer and Ipsen. A.H. is an employee of Ipsen. F.E. is an employee of Ipsen. P.C. has received unrestricted research and educational grants from Ipsen, Novartis, and Pfizer as Head of the Department of Endocrinology and Reproductive Diseases, Hôpitaux Universitaires Paris-Sud. P.C. has served as investigator (principal or coordinator) for clinical trials funded by Novartis, Pfizer, Ipsen, Italfarmaco, and Antisense Therapeutics. P.C. is a member of Advisory Boards for Ipsen and Novartis. P.C. has given lectures for Ipsen, Novartis, and Pfizer. All fees and honoraria are paid to his Institution.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.